Results 321 to 330 of about 87,437 (368)
Some of the next articles are maybe not open access.
Cytarabine for Herpesvirus Infections
JAMA: The Journal of the American Medical Association, 1972The antileukemic agent cytarabine has recently been used to treat herpesvirus infections, but the regimens advocated for this purpose are high-dose prolonged infusions (100 mg/sq m of body surface per day for five days). The use of cytarabine as an antiviral agent has been restricted by the toxic effects produced with these regimens.
William Hryniuk +3 more
openaire +3 more sources
2009
Publisher Summary This chapter describes cytarabine, its nomenclature, formulae, preparation methods, physical characteristics, analytical methods, biological analysis, pharmacokinetics, metabolism, stability, and pharmacology. Cytarabine, a pyrimidine nucleoside analog, is an antimetabolite, antineo-plastic, which inhibits the synthesis of ...
Hussein I. El-Subbagh +1 more
openaire +3 more sources
Publisher Summary This chapter describes cytarabine, its nomenclature, formulae, preparation methods, physical characteristics, analytical methods, biological analysis, pharmacokinetics, metabolism, stability, and pharmacology. Cytarabine, a pyrimidine nucleoside analog, is an antimetabolite, antineo-plastic, which inhibits the synthesis of ...
Hussein I. El-Subbagh +1 more
openaire +3 more sources
Febrile Response to Cytarabine
JAMA: The Journal of the American Medical Association, 1974To the Editor.— During our increased utilization of cytarabine (Cytosar) especially in therapy of acute leukemia, we noted that four of approximately 105 of our patients treated had recurrent febrile responses during therapy with the drug. This fever may be either a single spike reaching 38 to 39 C (100 to 102 F) in an otherwise afebrile patient, or ...
Dale B. Kellon +3 more
openaire +3 more sources
Clinical Pharmacokinetics of Cytarabine Formulations [PDF]
Clinical Pharmacokinetics, 2002 Cytarabine (cytosine arabinoside, Ara-C) is an effective chemotherapeutic agent for the treatment of acute myelogenous leukaemia and lymphocytic leukaemias. As cytarabine is an S-phase-specific drug, prolonged exposure of cells to cytotoxic concentrations is critical to achieve maximum cytotoxic activity.
Masahiro Nakano +2 more
openaire +2 more sources
Drug Safety, 1990
The principal toxicity of standard induction regimens for acute non-lymphocytic leukemia (ANLL) [including cytarabine (ARA-C) 100 mg/m2 for 7 days plus an anthracycline] is myelotoxicity, leading to death in at least 25% of cases during induction in non-selected patients.
openaire +3 more sources
The principal toxicity of standard induction regimens for acute non-lymphocytic leukemia (ANLL) [including cytarabine (ARA-C) 100 mg/m2 for 7 days plus an anthracycline] is myelotoxicity, leading to death in at least 25% of cases during induction in non-selected patients.
openaire +3 more sources
Cytarabine Dose for Acute Myeloid Leukemia
New England Journal of Medicine, 2011Cytarabine (ara-C) is an important drug in the treatment of acute myeloid leukemia (AML). High-dose cytarabine (2000 to 3000 mg per square meter of body-surface area) is toxic but results in higher rates of relapse-free survival than does the conventional dose of 100 to 400 mg per square meter.
Löwenberg, B +17 more
openaire +14 more sources
Clinical Pharmacology & Therapeutics, 1970
Warning. Only physicians experienced in cancer chemotherapy should use Cytosar. For induction therapy patients should be hospitalized in a facility with laboratory and supportive resources sufficient to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity.
openaire +2 more sources
Warning. Only physicians experienced in cancer chemotherapy should use Cytosar. For induction therapy patients should be hospitalized in a facility with laboratory and supportive resources sufficient to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity.
openaire +2 more sources
Synthesis of radiolabeled cytarabine conjugates
Bioorganic & Medicinal Chemistry Letters, 2009N4-Modified, novel Ara-C conjugate capable of radiolabeling with gamma ray-emitting ((99m)Tc) as well as positron emitting ((18)F) radionuclides, that is, N4-hydrazine derivative was synthesized. The radiolabeling of N4-(hydrazinonicotinyl)-1-beta-arabinofuranosyl cytosine (HAra-C) with (99m)Tc was performed with over 95% labeling yield.
Prachi Vilekar +2 more
openaire +3 more sources
Archives of Pediatrics & Adolescent Medicine, 1988
In Reply .—Dr Slater indicates that the symptoms and signs of the patient we recently described may not have been caused by generalized anaphylaxis but rather by hypoglycemia or hypocalcemia. The most likely alternative diagnosis, we believe, would have been a vasovagal attack 1,2 ; however, none of these conditions would have resulted in swelling of ...
Michael C. Greeff +5 more
openaire +2 more sources
In Reply .—Dr Slater indicates that the symptoms and signs of the patient we recently described may not have been caused by generalized anaphylaxis but rather by hypoglycemia or hypocalcemia. The most likely alternative diagnosis, we believe, would have been a vasovagal attack 1,2 ; however, none of these conditions would have resulted in swelling of ...
Michael C. Greeff +5 more
openaire +2 more sources
Effects of high-dose cytarabine
Clinical Pharmacology and Therapeutics, 1982Plasma, urine, cerebrospinal fluid, and tear concentrations of cytarabine (ara-C) were measured in 15 patients receiving 3 gm/m2 IV ara-C given as a 1 hr infusion every 12 hr for 6 days. The two assay methods used for measuring ara-C concentrations (high-pressure liquid chromatography and radioimmunoassay) gave much the same results.
Steven N. Wolff +9 more
openaire +3 more sources